Tendler S, De Gregorio R, Balderes P, Michel AL, Hoang TT, Bauer D, Tully KM, Korsen JA, Lorenz IC, Khan AG, Carter L, Vergnolle O, Lebedeva IV, Nyakatura EK, Bodei L, Morris MJ, Poirier JT, Rudin CM, Lewis JS (2026) Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers. Proc Natl Acad Sci U S A 123(6):e2505785123. doi: 10.1073/pnas.2505785123 PMID: 41628333
Objective: To report on the development of anti-DLL3 radioimmunoconjugates for use as either a diagnostic imaging tracer or a therapeutic agent. Delta-like ligand 3 (DLL3) is a tumor-selective cell surface protein upregulated in high-grade neuroendocrine tumors, including small-cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC).
Summary: The authors generated a panel of human monoclonal antibodies targeting human DLL3 by immunizing transgenic mice engineered with a human immunoglobulin repertoire. Six select candidates were reformatted as human IgG4 anti-DLL3 mAbs.
Usage: NCI-H82 cells were seeded in a 96-well plate and incubated with serial dilutions of tested antibodies, premixed with the Fab–ZAP (IT-48) for 72 h.
Related Products: Fab-ZAP mouse (Cat. #IT-48)